Nonsyndromic congenital nail disorder 6

disease
On this page

Also known as absent nails and dystrophic nailsnail disorder, nonsyndromic congenital, 6NDNC6nonsyndromic congenital nail disorder type 6onychodystrophy-anonychia

Summary

Nonsyndromic congenital nail disorder 6 (MONDO:0007135) is a disease. A subtype of isolated congenital anonychia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namenonsyndromic congenital nail disorder 6
Mondo IDMONDO:0007135
OMIM107000
DOIDDOID:0080084
UMLSC3275544
MedGen477175
GARD0015040
Is cancer (heuristic)no

Also known as: absent nails and dystrophic nails · nail disorder, nonsyndromic congenital, 6 · NDNC6 · nonsyndromic congenital nail disorder type 6 · onychodystrophy-anonychia

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › nail disorderinherited isolated nail anomaly › isolated congenital anonychia › nonsyndromic congenital nail disorder 6

Related subtypes (2): nonsyndromic congenital nail disorder 4, anonychia-onychodystrophy syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.